A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
about
Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trialOral fluoropyrimidines among the new drugs for patients with metastatic breast cancerUnliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpointGemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.The efficacy of docetaxel and cisplatin combination chemotherapy for the treatment of advanced gastric cancer after failing to 5-fluorouracil based chemotherapyTaxane pathway.Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.Docetaxel in the management of ovarian cancer.Docetaxel in the treatment of breast cancer: current experience and future prospects.Taxanes for the treatment of metastatic breast cancer.Docetaxel for the post-surgery treatment of patients with node-positive breast cancerIxabepilone for the treatment of breast cancer.Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane.Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases.Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy.Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer.Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin.Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.
P2860
Q24799659-FF767D32-DA68-4D38-8B41-DDD06F55F8A9Q28366029-8C7BF049-E10D-45E7-84DF-A74D107647EEQ30560953-2B2D9BF2-388B-48B5-8D08-21233C81A273Q33340278-D4C56F4A-3AC4-4C63-B67B-ABE0BA90838DQ33746810-75911BE4-6F2A-4212-A39D-1A55869CF170Q34390370-80F6D114-9A0F-499C-B96B-D385A920DF90Q35145663-AC20A0BC-0A8A-400A-8D26-E65E422F4F8EQ36118370-158444B7-235B-4575-BDA6-4F76DB39E6C7Q36235546-AEC4974E-C2EF-41B4-938E-3E7CD9368059Q36364762-29547067-0D42-4F9C-A6C3-DD8CF80CCC72Q36823602-FC0583FE-D41A-497B-8291-6EBB63D24B1AQ37876407-FB92E71D-40E9-47F4-98D7-6C54B84E7538Q37957744-E69C33FA-9110-428E-8B1D-BB4E064A7BCFQ39252283-11008F01-8E55-4A9B-B8F6-8EB1613C4C29Q40247703-C1BAD965-332F-4D90-8511-79836DCFC154Q40588127-26A6DFBD-1D82-4D17-AC8A-621C9C948108Q40591941-91683884-7BC5-455D-9533-3336EF444467Q40602756-EB084213-A229-49F5-97EC-7068AE86CF60Q43635627-7698A7DB-ACF4-42D4-A245-79EE5FE803B2Q43824330-B7129B24-5DE1-4288-BC64-1CB72ACD01D4Q43968364-FA644289-2D2B-48AA-8ED4-C970762FA516Q44180975-6CBEA6D4-20F1-407E-8BC2-61F88E0FA672Q44915628-59BE36BA-FCC7-42EC-A74F-DD114591AEEBQ49787954-C7342E55-9A39-4F78-96E7-B3657DFF1802Q50957199-4A4AECF0-D143-4840-9027-B825F4FFE7EBQ54631608-42CA2584-84FD-474B-82B3-B163EA7A4DBD
P2860
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
A phase II study of docetaxel ...... tant metastatic breast cancer.
@en
A phase II study of docetaxel ...... tant metastatic breast cancer.
@nl
type
label
A phase II study of docetaxel ...... tant metastatic breast cancer.
@en
A phase II study of docetaxel ...... tant metastatic breast cancer.
@nl
prefLabel
A phase II study of docetaxel ...... tant metastatic breast cancer.
@en
A phase II study of docetaxel ...... tant metastatic breast cancer.
@nl
P2093
P1476
A phase II study of docetaxel ...... tant metastatic breast cancer.
@en
P2093
D D Von Hoff
D J Booser
F A Holmes
G N Hortobagyi
H A Burris
L Esparza-Guerra
M W Schottstaedt
P M Ravdin
R G Mennel
P304
P356
10.1200/JCO.1998.16.10.3362
P407
P577
1998-10-01T00:00:00Z